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Abstract
Background The Cambridge Pulmonary Hypertension Out-
come Review (CAMPHOR) is the first disease-specific in-
strument for pulmonary arterial hypertension (PAH) to as-
sess patient-perceived symptoms, activity limitations and
quality of life. To be able to use this questionnaire in the
Netherlands, the aim of the study was to translate and val-
idate this instrument for the Dutch-speaking population.
Methods First the CAMPHOR was translated into Dutch
(by means of a bilingual and a lay panel) and field-tested
by means of cognitive debriefing interviews with ten PAH
patients. For psychometric evaluation, 80 patients with
PAH or chronic thromboembolic pulmonary hypertension
(CTEPH) were asked to complete the CAMPHOR twice
over a two-week period. To test for construct validity,
participants also completed the Nottingham Health Profile
(NHP).
Results The Dutch version of the CAMPHOR showed
high internal consistency for all scales (Cronbach’s alpha
0.89–0.91) and excellent reproducibility over two weeks
(reliability coefficients 0.87–0.91). Concurrent validity
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showed that the CAMPHOR scales correlated as expected
with the NHP scales. The CAMPHOR was able to dis-
tinguish between patient groups based on self-reported
general health status, disease severity and NYHA classi-
fication demonstrating evidence of known group validity.
The CAMPHOR activity limitations scale correlated mod-
erately with the distance walked during the 6-minute walk
test (r = –0.47, p < 0.01) and the symptoms scale with the
Borg dyspnoea score (r = 0.51, p < 0.01).
Conclusion The Dutch version of the CAMPHOR is a re-
liable and valid measure of quality of life and health status
in patients with PAH and CTEPH is recommended for use
in routine care and in clinical research.
Keywords Pulmonary arterial hypertension · Chronic
thromboembolic pulmonary hypertension · CAMPHOR
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Background
Pulmonary arterial hypertension (PAH) is a progressive dis-
ease of the pulmonary vasculature, leading to increased
pulmonary vascular resistance ultimately resulting in right
heart failure and premature death [1]. PAH can affect per-
sons of all ages, and females are more affected than males
[1, 2]. Symptoms include breathlessness, fatigue, chest
pain, palpitations, ankle oedema and syncope [1]. Un-
fortunately, it is not possible to cure the disease with the
currently available treatments. The aim of therapy is to
lengthen survival time, to ameliorate symptoms, to improve
quality of life and to reduce the number of hospitalisa-
tions [3]. Chronic thromboembolic hypertension (CTEPH)
is a form of precapillary PH. Patients with non-operable
CTEPH suffer from the same symptoms as patients with
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Tab. 1 Demographic and patient characteristics
Characteristics Patients (n = 76) Percentage (%)
Sex Male 17 22.3
Female 59 77.7
Age in years Mean 56
Median 59.5
Range 20–79
Diagnosis in years Mean 7.1
Median 4.2
Range 0–50
Aetiology IPAH 26 34.2
HPAH 4 5.3
Congenital heart disease 5 6.6
Connective tissue disease 11 14.5
HIV 3 3.9
Porto pulmonary 3 3.9
PVOD 1 1.3
Other 3 3.9
CTEPH 20 26.3
NYHA classification 1 0 0
2 56 73.7
3 20 26.3
4 0 0
Treatment ERA monotherapy 13 17.1
PDE-5 inhibitor monotherapy 7 9.2
Riociguat 2 2.6
Duo therapy: ERA and PDE-5 inhibitor 30 39.5
Prostacyclin monotherapy 6 7.9
Prostacyclin and PDE-5 inhibitor 2 2.6
Prostacyclin and ERA 1 1.3
Triple therapy prostacyclin, ERA and PDE-5 inhibitor 11 14.5
Require oxygen No
Yes
61
14
81.3
18.7
6-minute walking distance in meters Mean 466
Median 472
Range 232–647
Missing 4
NT-proBNP in pmol/ml Mean 53.4
Median 24.8
Range 3.9–439.2
IPAH idiopathic pulmonary arterial hypertension, HPAP heritable pulmonary arterial hypertension, PVOD pulmonary veno-occlusive disease,
CTEPH chronic thromboembolic pulmonary hypertension, ERA endothelin receptor antagonist, PDE-5 inhibitor phosphodiesterase-5 inhibitor
PAH and despite treatment with specific PAH medication
have a poor life expectancy [4, 5].
In spite of the current treatment options, health-related
quality of life (HRQL) is impaired in most patients suffer-
ing from PAH [6–9]. HRQL should be measured with an
appropriate questionnaire [10]. Generic HRQL measures
employed in PAH populations are of limited value in the
assessment of PAH, since these do not take into account all
aspects of the disease and its treatment [11–14]. Therefore,
a disease-specific outcome measure for patients with PAH
has been developed, the Cambridge Pulmonary Hyperten-
sion Outcome Review (CAMPHOR) [15]. The question-
naire comprises three scales that assess overall symptoms
(25 items), activity limitations (15 items) and quality of life
(15 items). This tool is designed for use in clinical practice
as well as clinical trials. This questionnaire has been used as
an outcome parameter in studies concerning PAH over the
last years [16–18]. The CAMPHOR health questionnaire
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Tab. 2 Disease information at time 1 (n = 76)
Number of
patients
Percentage (%)
Self-reported general health
Poor 6 7.9
Fair 32 42.1
Good 32 42.1
Very good 6 7.9
Self-reported severity of disease
No symptoms 8 10.7
Mild 28 37.3
Moderate 35 46.7
Quite severe 3 4.0
Very severe 1 1.3
Flare up
No 72 94.7
Yes 4 5.3
has been translated and validated in several languages for
several countries [19–23]. This paper describes the adapta-
tion and the validation of CAMPHOR for Dutch-speaking
population in the Netherlands.
Methods
The adaptation of the CAMPHOR questionnaire was con-
ducted in two PH centres in the Netherlands, the Erasmus
University Medical Center in Rotterdam and the VU Uni-
versity Medical Center in Amsterdam. The process con-
sisted of three stages: translation (by means of a bilingual
and a lay panel), cognitive debriefing interviews with ten
PAH patients and validation by means of a postal validation
study. The study was approved by the ethics committees of
both centres.
Translation process
A professional translation panel of six individuals who were
fluent in both English and Dutch, led by the local investi-
gator’s representative and a research scientist from Galen
Research, produced the first translation. A separate lay
panel consisting of five individuals of average educational
level (3 men and 2 women aged between 21 and 67 years)
discussed the proposed wording of the items and decided
whether these were acceptable or required adjustments to
improve the clarity and to make the sentences sound more
natural. The local investigator evaluated and discussed the
changes made with the scientist from Galen Research.
Cognitive debriefing interviews
The draft version of the instrument was tested with ten
patients, via one-to-one semi-structured interviews. A rep-
resentative selection of PAH patients was made based on
gender, age, severity of PAH and social background. The
respondents were asked to complete the questionnaire in
the presence of an interviewer who observed whether any
problems were experienced. Respondents were required to
provide feedback on their comprehension of the measure
and the relevance of the items.
Postal validation survey
During a consecutive three-month period from Septem-
ber 2014 to December 2014, 80 Dutch-speaking patients
(who were able to read the Dutch language), suffering
from pre-capillary PAH (WHO group 1) or CTEPH (WHO
group 4), were asked to complete the new language ver-
sion of the CAMPHOR and the Nottingham Health Profile
(NHP) on the day of their clinic visit and the CAMPHOR
questionnaire again after two weeks.
The NHP is a generic measure of perceived distress con-
sisting of 38 items divided into six sections (energy level,
pain, emotional reactions, sleep, social isolation and phys-
ical ability) [24, 25]. In both questionnaires higher scores
indicate worse health status.
Baseline characteristics were obtained (sex, age, employ-
ment status) and illness information (duration of PH, per-
ceived general health, self-perceived disease severity, oxy-
gen use) was also collected. The NYHA functional class
was determined, a six-minute walk test (6MWT) was per-
formed and the NT-pro BNP level was measured.
Patients were asked to complete the questionnaires at
home and to return the questionnaires by post in pre-ad-
dressed, stamped envelopes. After two weeks, they received
a phone call to remind them to fill in the second CAMPHOR
questionnaire and to inquire about possible changes in their
physical health.
Withdrawal of patients
Patients who did not complete more than 85 % of a ques-
tionnaire were withdrawn from the analysis. For the test-
retest reliability, patients were excluded if they were not
clinically stable.
Data analysis
Continuous variables are expressed as mean ± SD. Internal
consistency of the CAMPHOR adaptation was evaluated by
determining Cronbach’s alpha coefficient. An alpha coeffi-
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Tab. 3 Questionnaire descriptive statistics
n Median (IQR) Mean (SD) Min–Max % scoring
minimum
% scoring
maximum
Time 1
CAMPHOR symptoms 76 4.0 (2.0–8.0) 5.3 (4.6) 0.0–25.0 13.2 0.0
CAMPHOR activities 76 4.0 (2.0–9.0) 5.6 (4.9) 0.0–30.0 14.5 0.0
CAMPHOR QoL 76 4.0 (1.0–8.0) 5.1 (4.9) 0.0–25.0 14.5 0.0
NHP
Energy scale 74 0.0 (0.0–33.3) 19.8 (32.6) 0.0–100.0 66.2 9.5
Pain scale 75 0.0 (0.0–0.0) 7.0 (18.4) 0.0–100.0 78.7 0.0
Emotional Reactions 75 0.0 (0.0–11.1) 10.8 (18.7) 0.0–100.0 58.7 1.3
Sleep scale 75 20.0 (0.0–40.0) 25.3 (30.2) 0.0–100.0 46.7 2.7
Social isolation 74 0.0 (0.0–0.0) 5.1 (13.7) 0.0–100.0 85.1 0.0
Physical mobility 74 12.5 (0.0–25.0) 15.4 (19.0) 0.0–100.0 47.3 0.0
NHP–D 73 2.0 (0.0–4.0) 2.9 (3.9) 0.0–24.0 32.9 0.0
Time 2
CAMPHOR Symptoms 74 6.0 (1.8–9.0) 5.9 (5.0) 0.0–25.0 16.2 0.0
CAMPHOR Activities 75 4.0 (2.0–9.0) 5.9 (5.1) 0.0–30.0 17.3 0.0
CAMPHOR QoL 74 3.0 (1.0–8.3) 4.9 (5.2) 0.0–25.0 21.6 0.0
cient >0.7 is considered to be the minimum value required
to indicate sufficient internal consistency.
Test re-test reliability (patient-specific agreement be-
tween two repeated administrations) was examined using
Spearman’s rank correlations. Correlation coefficients
above 0.85 indicate good reproducibility [26]. Convergent
validity was assessed with the NHP as the comparator
instrument using Spearman’s rank correlations. Known
group validity was tested by Mann-Whitney U test. Cor-
relation between CAMPHOR scores, demographic factors,
the results of the 6MWT (including Borg scores) and NT-
pro BNP levels was assessed using Spearman’s rank cor-
relations. A p-value of <0.05 was considered statistically
significant.
Results
Bilingual panel
The group reached consensus on the appropriate wording
for most items. A few phrases could not be translated liter-
ally. For example, one item from the symptoms scale; ‘My
stamina levels are low’ was translated as ‘Mijn lichameli-
jke conditie is slecht’ (literally: ‘My physical condition is
weak’). For a few items consensus could not be reached
and alternative versions of these items were taken forward
for consideration by the lay translation panel.
Lay panel
Some expressions were altered from the original translation
into more commonly used Dutch. For example, for item 9
of the symptoms scale: ‘I soon run out of energy’. This
sentence was translated as; ‘Mijn energie is snel op’. The
panel felt that this translation was too literal. They instead
proposed: ‘Ik heb weinig energie’ (literally: ‘I have little
energy’).
Cognitive debriefing interviews
Ten patients were interviewed (6 females, 4 males, mean
age 49.1, range 20–77 years, PH symptoms ranged from
mild to quite severe). Average time for completion was
12.6 minutes (range 6–24 minutes, median 11.5 minutes).
Overall patients thought the questionnaire was appropriate
and applicable. Some patients found it hard to choose be-
tween the ‘Yes’ or the ‘No’ response format, and would
have liked the option of ‘Sometimes’. For the activity lim-
itations scale, the response option ‘Doing it on your own
with problems’ was changed into ‘With difficulties doing it
on your own’. In the quality of life section item 17; ‘I feel
that I’m losing my role in life’, translated as; ‘Ik voel dat ik
mijn rol(len) [verantwoordelijkheden] in het leven verlies’
was considered to be a difficult question by the majority of
the patients.
Postal validation survey
From the 80 patients who were asked to participate, 76 com-
pleted and returned the questionnaires. Of these only
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Tab. 4 Cronbach’s alpha coefficients
Time 1 Time 2
CAMPHOR symptoms 0.89 0.89
CAMPHOR activities 0.91 0.90
CAMPHOR QoL 0.89 0.91
Tab. 5 Correlation coefficients between CAMPHOR scales and NHP,
6MWT and NT-proBNP
Symptoms Activities QoL
NHP
Energy scale 0.71* 0.65* 0.66*
Pain scale 0.38* 0.38* 0.42*
Emotional reactions 0.43* 0.24** 0.37*
Sleep scale 0.32* 0.22 0.38*
Social isolation 0.23 0.34* 0.39*
Physical mobility 0.67* 0.76* 0.61*
NHP-D 0.58* 0.49* 0.63*
6MWT
Distance walked(m) –0.34* –0.47* –0.42*
Borg dyspnoea score 0.51* 0.49* 0.32*
NT-proBNP –0.08 –0.08 0.10
Values shown represent Spearman’s rank correlation coefficients
*p < 0.01; **p < 0.05
0.14 % of the items were missing. Missing items from the
CAMPHOR as well as the NHP questionnaire were han-
dled according to the manuals. Demographic and disease
characteristics of the respondents are listed in Tab. 1. The
cohort consisted of 59 females and 17 males, which is con-
sistent with the gender ratio in a PAH population. Disease
information is listed in Tab. 2. The descriptive statistics for
the questionnaires at both time points are shown in Tab. 3.
High floor effects (high number of patients scoring the
minimum) were observed in the NHP subscales, but not in
the CAMPHOR scales.
Internal consistency
For all three CAMPHOR scales, Cronbach’s alpha coeffi-
cients were above 0.8, indicating high internal consistency
(detailed in Tab. 4).
Test-retest reliability
Test-retest reliability was excellent for all three scales, (0.87
for symptoms, 0.91 for activity and 0.87 for quality of life),
which demonstrates low levels of random measurement er-
ror.
Convergent validity
The CAMPHOR symptoms scale correlated strongly with
the energy and physical mobility scales of the NHP, show-
ing the importance of these factors on PAH symptoma-
tology. It also correlated moderately with Borg dyspnoea
scores. There were significant correlations between the
CAMPHOR QoL scale and the NHP energy scale, physical
mobility and NHP-D (summation of sub-set of NHP items
scores) indicating that multiple factors influence QoL. As
expected, the activity limitations scale showed the strongest
correlation with the NHP physical mobility and 6MWT. The
correlation coefficients between CAMPHOR scales and the
NHP are listed in Tab. 5.
No significant correlations were demonstrated between
the CAMPHOR scales and the NT-pro BNP (Tab. 5).
Association of CAMPHOR scores and demographic
factors
No significant differences in the CAMPHOR scores were
found between patients grouped by age. However, signifi-
cant differences were shown in the scores of symptoms and
QoL scales between males and females. Females scored
higher on these two scales compared with males. A chi-
square test of independence was performed to assess the
relation between gender and self-reported severity of dis-
ease. No significant association was found between these
variables (χ2 (1, n = 75) = 0.08, p = 0.93). Similarly, no sig-
nificant relationship was found between gender and NYHA
class (χ2 (1, n = 76) = 1.1, p = 0.74). The relation between
gender and cause of PH was also investigated, but again no
significant association was found (χ2 (7, n = 76) = 8.5, p =
0.29).
Known group validity
CAMPHOR scales scores were able to discriminate be-
tween patients based on perceived general health (‘very
good/good’ versus ‘fair/poor’) and severity of disease (‘no
symptoms/mild’ versus ‘moderate/severe’). Patients with
worse perceived general health (Fig. 1) and more severe
PAH (Fig. 2) had higher scores for all three scales of the
CAMPHOR.
Patients in NYHA class 3 showed significantly higher
scores on all three CAMPHOR scales compared with pa-
tients in NYHA class 2 (Fig. 3).
Patients grouped based on the distance walked during
6MWT (below and above the mean value of 466 metres)
showed significant differences in all CAMPHOR scales
(Fig. 4).
No differences were observed in the CAMPHOR sub-
scales between PAH and CTEPH patients (16 patients in
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Fig. 1 Median CAMPHOR scales scores for self-reported general
health tested with Mann Whitney U. Interquartile ranges (IQR) for the
Camphor scales scores for very good/good and fair/poor, respectively,
are: Symptoms 0.8–4.3 and 4.0–11.0; Activities 1.0–5.0 and 3.0–10.0;
Qol 1.0–5.0 and 1.8–10.0
Fig. 2 Median CAMPHOR scales scores for self-reported disease
severity tested with the Mann-Whitney U test. Interquartile ranges
(IQR) for the Camphor scales scores for no symptoms/mild and mod-
erate/severe, respectively, are: Symptoms 0.0–3.0 and 5.0–11.0; Activ-
ities 0.3–5.8 and 3.0–10.0; Qol 0.0–5.0 and 3.0–10.0
NYHA class 2 and four patients in NYHA class 3), tested
by the Mann-Whitney U test: CAMPHOR symptoms p =
0.59, CAMPHOR activities p = 0.92 and CAMPHOR qual-
ity of life p = 0.94.
Discussion
This study demonstrates that the new adaptation of the
CAMPHOR for Dutch-speaking participants in the Nether-
lands is valid and reliable. The objective of adapting the
questionnaire is to ensure that items are understood in the
same way in different countries and that conceptual equiv-
alence rather than linguistic equivalence is achieved in the
translated items. Moreover, it is vital that translated items
are expressed in common (everyday) language. No major
problems were encountered during the translation process.
Fig. 3 Median CAMPHOR scores and NYHA classification tested
with the Mann-Whitney U test. Interquartile ranges (IQR) for the Cam-
phor scales scores for class II and class III, respectively, are: Symptoms
1.0–7.0 and 4.0–11.8; Activities 2.0–8.0 and 3.0–12.5; Qol 1.0–5.8 and
2.3–11.5
Fig. 4 Group validity of six-minute walk distance ≥ 466 m and
< 466 m and median CAMPHOR scales scores using the Mann-Whit-
ney U test. Interquartile ranges (IQR) for the Camphor scales scores
for ≥466 m and 466 m, respectively, are: Symptoms 1.0–3.0 and
3.0–9.8; Activities 1.0–5.0 and 3.0–12.8; Qol 0.0–5.8 and 4.0–8.0
Descriptive statistics showed the CAMPHOR had low
floor effects and no ceiling effects, which indicates the
CAMPHOR is well targeted to the PAH population. Con-
sequently, the measure should be sensitive and responsive
in clinical studies (e. g. in longitudinal studies). In contrast,
the NHP showed very high floor effects indicating patients
with the lowest possible score cannot be distinguished from
each other, which reduces sensitivity.
Cronbach’s alpha coefficients were above 0.8 for the
three CAMPHOR scales, indicating that the items were re-
lated adequately to form scales. Test-retest reliability was
excellent for all three scales showing the scales have low
levels of random measurement error.
The CAMPHOR scales showed different levels of asso-
ciation with the scales of the NHP, demonstrating evidence
of convergent validity. As expected, CAMPHOR activities
correlated most strongly with the NHP physical mobility
scale and 6MWT as was also shown by Cima et al. in the
German adaptation of the CAMPHOR [22].
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Patients with worse perceived general health and more
severe PAH had higher scores for all three scales of the
CAMPHOR scores showing that the scales could distin-
guish appropriately between groups of known importance.
Females scored higher on the scales of symptoms and
QoL compared with males. Further analyses were per-
formed to investigate this difference. The relation between
gender and self-reported severity of disease as well as gen-
der and NYHA class and gender and cause of PAH was
assessed. No significant association was found between
gender and the investigated variables. Based on these find-
ings it was unclear what contributed to the differences be-
tween gender groups. However, due to the relatively small
sample of males the results could be spurious.
The sample of patients included in this study seemed to
have less severe disease than the sample included in the
original paper describing the development of the CAM-
PHOR questionnaire. One explanation may be that with
the currently available treatment, including triple therapy,
less patients are now in NYHA class 4. Another explana-
tion might be that only patients who visited the outpatient
clinic were asked to participate in the study. In this way
the very severe patients, who were hospitalised during this
period (for example those waiting for lung transplantation),
were not included.
However, the CAMPHOR scores were able to clearly
distinguish between patients in NYHA class 2 and NYHA
class 3. Moreover, the results of the 6MWT correlate well
with the CAMPHOR scale scores.
Conclusions
The new Dutch language version of the CAMPHOR is
a valid and reliable instrument for assessment of health-
related quality of life in PAH and CTEPH patients and is
recommended for use in clinical practice. Moreover the
CAMPHOR provides a valid tool for a single-point mea-
surement in cross-sectional studies.
Acknowledgements The authors thank their PH nursing team for all
their support.
Funding This study was supported by a grant from GSK, the Nether-
lands.
Conflict of interest M. Wapenaar, J. Twiss, M. Wagenaar, P. Seij-
kens, L. van den Toorn, J. Stepanous, A. Heaney, A. van den Bosch
and K. A. Boomars state that there are no conflicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Galie N, Humbert M, Vachiery J-L, et al. ERS/ESC guidelines.
Guidelines for the diagnosis and treatment of pulmonary hyperten-
sion. Eur Respir J. 2015;46:903–975.
2. McGoon MD, Benaz RL, Escribano-Scubias P, et al. Pulmonary
Arterial Hypertension. Epidemiology and Registries. J Am Coll.
2013;62:D51–D59.
3. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term
survival from the time of diagnosis in pulmonary arterial hyperten-
sion from the REVEAL registry. Chest. 2012;142:448–456.
4. Kim N, Delcroix M, Jenkins DP, et al. Chronic Thomboembolic
Pulmonary Hypertension. J Am Coll Cardiol. 2013;62:D92–9.
5. Schölzel BE, Snijder RJ, Mager JJ, et al. Chronic thromboembolic
pulmonary hypertension. Neth Heart J. 2014;22:533–541.
6. Shafazand S, Goldstein MK, Doyle RL, et al. Health-Related Qual-
ity of life in patients with pulmonary arterial hypertension. Chest.
2004;126:1452–1459.
7. Looper KL, Pierre A, Dunkley DM, et al. Depressive symptoms in
relation to physical functioning in pulmonary hypertension. J Psy-
chosom Res. 2009;66:221–225.
8. Vanhoof J, Delcroix M, Vanvelde E, et al. Emotional symptoms
and quality of life in patients with pulmonary arterial hypertension.
J Heart Lung Transplant. 2014;33:800–808.
9. McCollister D, Beutz M, McLaughlin V, et al. Depressive symp-
toms in pulmonary hypertension: prevalence and association with
functional status. Psychosomatics. 2010;51(339-339):e8.
10. Terwee CB, Bot SDM, Boer M de, et al. Quality criteria were pro-
posed for measurement properties of health status questionnaires.
J Clin Epidemiol. 2007;60:34–42.
11. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous
epoprostenol infusion in primary pulmonary hypertension: prog-
nostic factors and survival. J Am Coll Cardiol. 2002;40:780–788.
12. McLaughlin VV, Shillington A, Rich S, et al. Survival in primary
pulmonary hypertension: the impact of epoprostenol therapy. Cir-
culation. 2002;106:1477–1482.
13. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pul-
monary arterial hypertension patients treated with subcutaneous tre-
postenil. Eur Respir J. 2006;28:1195–1203.
14. Blok IM, Riel ACMJ van, Schuuring MJ, et al. Decrease in qual-
ity of life predicts mortality in adult patients with pulmonary ar-
terial hypertension due to congenital heart disease. Neth Heart J.
2015;23:278–284.
15. McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pul-
monary Hypertension Outcome Review (CAMPHOR). A measure
of health related quality of life and quality of life for patients with
pulmonary hypertension. Qual Life Res. 2006;15:103–115.
16. Chen H, Rosenzweig E, Gotzkowsky SK, et al. Treatment sat-
isfaction is associated with improved quality of life in patients
treated with inhaled trepostenil for pulmonary arterial hyperten-
sion. Health Qual Life Outcomes. 2013;11:31.
17. Chan L, Chin L, Kennedy M, et al. Benefits of intensive treadmill
exercise training on cardiorespiratory function and quality of life in
patients with pulmonary hypertension. Chest. 2013;143:333–343.
18. McCabe C, Bennet M, Doughty N, et al. Patient-reported outcomes
assessed by CAMPHOR questionnaire predict clinical deterioration
in idiopathic pulmonary arterial hypertension and chronic throm-
boembolic pulmonary hypertension. Chest. 2013;144:522–530.
19. Coffin D, Duval K, Martel S, et al. Adaptation of the Cambridge
Pulmonary Hypertension Outcome Review into French-Canadian
and English-Canadian. Can Respir J. 2008;15:77–83.
20. Coffin D, Duval K, Martel S, et al. United States Validation
of the Cambridge Pulmonary Hypertension Outcome Review
(CAPMHOR. J Heart Lung Transplant. 2008;27:124–130.
424 Neth Heart J (2016) 24:417–424
21. Ganderton L, Jenkins S, McKenna S, et al. Validation of the Cam-
bridge Pulmonary Hypertension Outcome Review (CAMPHOR)
for the Australian and New Zealand population. Respirology.
2011;16:1235–1240.
22. Cima K, Twiss J, Speich R, et al. The German adaptation of the
Cambridge pulmonary hypertension outcome review (CAMPHOR.
Health Qual Life Outcomes. 2012;10:110–118.
23. Selmovic N, Rundqvist B, Kjork E, et al. Adaptation and valida-
tion of the Cambridge pulmonary hypertension review for Sweden.
Scand J Public Health. 2012;40:777–83.
24. Hunt SM, McKenna SP, McEwen J, et al. The Nottingham Health
Profile: Subjective Health Status and Medical Consultations. Soc
Sci Med A;15A;221–9.
25. Erdman RAM, Passchier J, Kooijman M, et al. The Dutch version
of the Nottingham Health Profile: investigations of psychometric
aspects. Psychol Rep. 1993;72:1027–1035.
26. Portney L, Watkins M. Correlation. In: Cohen M, editor. Founda-
tions of Clinical Research: Applications to Practise, 3rd edn. New
Jersey: Pearson Education; 2009. pp. 523–538.
